Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obexelimab - Zenas Biopharma

Next Previous
Drug Profile

Obexelimab - Zenas Biopharma

Alternative Names: AMG 729; Humanised Fc-engineered monoclonal antibody against CD19 - Xencor; XmAb® 5871

Latest Information Update: 11 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Xencor; Zenas BioPharma
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Immunoglobulin G4-related disease; Multiple sclerosis
  • Phase II Systemic lupus erythematosus
  • No development reported Autoimmune disorders
  • Discontinued Autoimmune haemolytic anaemia; Rheumatoid arthritis

Most Recent Events

  • 09 Feb 2026 Efficacy and adverse events data from a Phase I/II MoonStone study in Multiple sclerosis released by Zenas BioPharma
  • 05 Jan 2026 Zenas BioPharma announces intention to submit Biologics License Application (BLA) to US FDA for Immunoglobulin G4 related disease (Prevention) in the second quarter of 2026 (SC)
  • 05 Jan 2026 Zenas BioPharma announces intention to submit Marketing Authorization Application to the EMA for Immunoglobulin G4 related disease (Prevention) in the second half of year 2026 (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top